Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study

被引：36
|
作者：
Flannery, Kyle [1 ]
Boyd, Marley [2 ]
Black-Shinn, Jenny [2 ]
Robert, Nicholas [2 ]
Kamat, Ashish M. [3 ]
机构：
[1] Merck & Co Inc, Kenilworth, NJ 07033 USA
[2] US Oncol Network McKesson Specialty Hlth, The Woodlands, TX 77380 USA
[3] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Urol, Houston, TX 77030 USA
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 12期
关键词：
bladder cancer; cisplatin eligible; patient outcomes; real-world utilization; treatment patterns; PHASE-II TRIAL; TRANSITIONAL-CELL CARCINOMA; UROTHELIAL CARCINOMA; PACLITAXEL; CISPLATIN; CARBOPLATIN; CHEMOTHERAPY; METHOTREXATE; VINBLASTINE; MULTICENTER;
D O I：
10.2217/fon-2018-0654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: Investigate the effectiveness of chemotherapy for first-line (1L) treatment of metastatic bladder cancer (mBC). Methods: Retrospective cohort study evaluating treatment patterns/outcomes in 1155 mBC patients receiving initial treatment in the community practice setting from January 2010 to June 2014, and followed through July 2016. Results: The most commonly utilized 1L and second-line (2L) regimens were platinum-based and taxane-based, respectively. Median (95% CI) OS for all patients from 1L initiation was 12.8 months (11.7-14.6), and median OS for all 2L regimens was 9.4 months (8.2-11.1). Conclusion: mBC patients eligible for and who received cis-based regimens experienced better OS results. Poor renal function was a key driver of cis-ineligibility. The various monotherapy and combination chemotherapy regimens in 2L produced relatively short OS outcomes.
引用
收藏
页码：1323 / 1334
页数：12
相关论文
共 50 条
  • [21] Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
    Boukovinas, Ioannis
    Androulakis, Nikolaos
    Kentepozidis, Nikolaos
    Polyzos, Aris
    Papakotoulas, Pavlos
    Ziras, Nikolaos
    Kotsakis, Athanasios
    Vardakis, Nikolaos
    Karampeazis, Athanasios
    Markos, Vassilis
    Kostakopoulos, Athanasios
    Constantinides, Constantine A.
    Samonis, George
    Mavroudis, Dimitris
    Georgoulias, Vassilis
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 351 - 356
  • [22] The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy
    Matsumura, Nagahide
    Nakamura, Yasushi
    Kohjimoto, Yasuo
    Inagaki, Takeshi
    Nanpo, Yoshihito
    Yasuoka, Hironao
    Ohashi, Yasuo
    Hara, Isao
    BJU INTERNATIONAL, 2011, 108 (2B) : E110 - E116
  • [23] A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer
    Grobet-Jeandin, Elisabeth
    Lenfant, Louis
    Mir, Carmen
    Giannarini, Gianluca
    Alcaraz, Antonio
    Albersen, Maarten
    Breda, Alberto
    Briganti, Alberto
    Roupret, Morgan
    Seisen, Thomas
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (03): : 251 - 262
  • [24] Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004-AURA trial)
    Chanza, Nieves Martinez
    Soukane, Louisa
    Barthelemy, Philippe
    Carnot, Aurelien
    Gil, Thierry
    Casert, Vinciane
    Vanhaudenarde, Vincent
    Sautois, Brieuc
    Staudacher, Lionel
    Van den Brande, Jan
    Culine, Stephane
    Seront, Emmanuel
    Gizzi, Marco
    Albisinni, Simone
    Tricard, Thibault
    Fantoni, Jean Christophe
    Paesmans, Marianne
    Caparica, Rafael
    Roumeguere, Thierry
    Awada, Ahmad
    BMC CANCER, 2021, 21 (01)
  • [25] Survival trends in metastatic bladder cancer in the United States: A population based study
    Shah, Binay Kumar
    Mandal, Rakesh
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (01) : 124 - 128
  • [26] The Impact of an Enrolment in Clinical Trial on Tolerance and Pathological Response for Patients Treated by Neoadjuvant MVAC Against an Invasive Bladder Cancer. A Retrospective Comparative Study
    Guignand, Alexis
    Bouleftour, Wafa
    Vassal, Cecile
    Tinquaut, Fabien
    Rivoirard, Romain
    Guillot, Aline
    CLINICAL GENITOURINARY CANCER, 2024, 22 (01) : e14 - e21.e3
  • [27] Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020
    Bertucci, Alexandre
    Cartier, Lysian
    Rollet, Armelle
    Boustany, Rania
    Hilgers, Werner
    CANCERS, 2023, 15 (07)
  • [28] Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review
    Parikh, Rohan
    Kurosky, Samantha K.
    Udall, Margarita
    Chang, Jane
    Cappelleri, Joseph C.
    Doherty, Jim P.
    Kaye, James A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (04) : 738 - 748
  • [29] Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter
    Papamichael, D
    Gallagher, CJ
    Oliver, RTD
    Johnson, PW
    Waxman, J
    BRITISH JOURNAL OF CANCER, 1997, 75 (04) : 606 - 607
  • [30] Survival of patients with metastatic bladder cancer in the Russian Federation: results of a multicenter registry study URRU
    Tsimafeyeu, I., V
    Alekseeva, G. N.
    Petkau, V. V.
    Zukov, R. A.
    Mazhbich, M. S.
    Semenov, A., V
    Statsenko, G. B.
    Novikova, O. Yu
    Zaytsev, I., V
    Popova, I. L.
    Gurina, L., I
    Mukhina, M. A.
    Vladimirova, L. Yu
    ONKOUROLOGIYA, 2021, 17 (03): : 102 - 109
12345